Table 1

Characteristics of patients without response after the second dose of vaccine treated with RTX for AIDs according to their seroconversion after the third dose



Non-responders
(n=53)
Responders
(n=9)
P value
Age (years), median (IQR)61 (45 (4–69)58 (52–72)0.31
Female sex, n (%)44 (83)6 (67)0.36
Underlying disease, n (%)
Rheumatoid arthritis37 (70)5 (56)0.45
Other AID16 (30)4 (44)
RTX treatment
Received an RTX infusion between doses 2 and 3, n (%)15 (28)3 (33)0.71
Time between the last RTX infusion and the third dose of vaccine (days), median (IQR)165 (124–252)187 (150–360)0.19
Less than 3 months between the last RTX infusion and the third dose of vaccine, n (%)10 (19)1 (11)0.99
Previous number of RTX injections, median (IQR)7 (4–10)6 (4–11)0.66
Antispike response to the second dose
Detectable but bellow 49 BAU/mL, n/n (%)2/48 (4)4/8 (50)0.0025
Antispike response to the third dose
Undetectable, n (%)36 (68)0NA
Detectable but below 49 BAU/mL n (%)17 (32)0NA
>49 and <243 BAU/mL, n (%)02 (22)NA
>243 BAU/mL, n (%)07 (78)NA
Vaccination scheme
Time between the third dose and serological assessment (days), median (IQR)49 (21–90)54 (19–97)0,9
Interval between second and third vaccine dose in days, median (IQR)84 (46–204)129 (96–182)0.41
Comedications
Corticosteroids n (%)20 (38)3 (33.3)0.99
Prednisone equivalent dose per day (mg), median (IQR)5 (5–6)5 (5–10)0.48
Methotrexate, n (%)33 (62)3 (33)0.15
  • Results are expressed as median and were compared using Fisher exact test for categorical variables and Mann-Whitney for continuous variables.

  • AID, autoimmune disease; BAU, binding antibody unit; NA, not applicable; RTX, rituximab.